logo

Elevation Oncology, Inc. (ELEV)



Trade ELEV now with
  Date
  Headline
5/25/2022 7:38:50 AM ELEV: FDA Grants Fast Track Designation To Seribantumab For Solid Tumors Harboring NRG1 Gene Fusions
5/6/2022 6:45:14 AM Wedbush Is Cutting Elevation Oncology, Inc. (ELEV) FY22 Estimate To -3.42 From -2.83
5/6/2022 6:44:57 AM Wedbush Is Lowering Elevation Oncology, Inc. (ELEV) Q4 22 Estimate To -0.96 From -0.80
5/6/2022 6:44:42 AM Wedbush Is Cutting Elevation Oncology, Inc. (ELEV) Q3 22 Estimate To -0.90 From -0.74
5/6/2022 6:44:27 AM Wedbush Is Cutting Elevation Oncology, Inc. (ELEV) Q2 22 Estimate To -0.82 From -0.68
5/6/2022 6:43:58 AM Wedbush Reiterates Elevation Oncology, Inc. (ELEV) At Outperform With $15 Down From $21 Price Target
5/5/2022 7:49:15 AM Elevation Oncology Q1 Net Loss $17.3 Mln Vs. Net Loss $5.1 Mln Last Year
3/14/2022 7:04:49 AM Elevation Oncology Appoints David Dornan As Chief Scientific Officer
3/3/2022 7:33:14 AM Elevation Oncology Q4 Net Loss $9.6 Mln Vs. Net Loss Of $8.9 Mln Prior Year
11/12/2021 7:35:11 AM Elevation Oncology Q3 Loss Per Share $0.53 Vs Loss $3.80 Last Year
7/20/2021 6:38:06 AM Wedbush Initiates Elevate, Inc. (ELEV) At Outperform With $27 Price Target
6/24/2021 8:59:40 PM Elevation Oncology Prices IPO Of 6.25 Mln Shares At $16/shr